Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension

Blood Pressure

Volumn 20, Issue SUPPL. 1, 2011, Pages 3-11

  Mallion, Jean Michel ^a   Omboni, Stefano ^b   Barton, John ^c   Van Mieghem, Walter ^d   Narkiewicz, Krzysztof ^e   Panzer, Peter Klaus ^f   Puig, Juan García ^g   Stefanadis, Christodoulos ^h   Zweiker, Robert ⁱ  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b ITALIAN INSTITUTE OF TELEMEDICINE   (Italy)

^c Portiuncula Hospital   (Ireland)

^d DEPARTMENT OF CARDIOLOGY   (Belgium)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f Hospital Universitario de La Paz ^*

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HIPPOKRATION HOSPITAL   (Greece)

ⁱ Leopold Auenbrugger University Medical School   (France)

Author keywords

Ambulatory blood pressure monitoring; elderly; essential hypertension; office blood pressure; olmesartan; ramipril

Indexed keywords

OLMESARTAN; RAMIPRIL;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CONSTIPATION; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; FLATULENCE; FOOT DISEASE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HAIR LOSS; HEADACHE; HEART RATE; HUMAN; HYPERTENSIVE CRISIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SITTING; STATISTICAL SIGNIFICANCE; STOMACH PAIN; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 79251497684     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.532332     Document Type: Article

References (43)

1. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-1518.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217-223.
3. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed). 1986;293:1145-1151
4. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.
5. Medical Research Council trial of treatment of hypertension in older adults: Principal results. MRC Working Party. BMJ. 1992;304:405-412.
6. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
7. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Pagé V, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14:1237-1245.
8. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255-3264.
9. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764.
10. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated sistoli hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000;160:211-220.
11. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
12. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: Current outcomes and control in the community. JAMA. 2005;294:466-472.
13. Ostchega Y, Dillon CF, Hughes JP, Carroll M, Yoon S. Trends in hypertension prevalence, awareness, treatment, and control in older U. S. adults: Data from the National Health and Nutrition Examination Survey. 1988 to 2004. J Am Geriatr Soc. 2007;55:1056-1065.
14. Rashidi A, Wright JT Jr. Drug treatment of hypertension in older hypertensives. Clin Geriatr Med. 2009;25:235-244.
15. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci. 2009;64:256-263.
16. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: Meta-analysis of randomised trials. BMJ. 2008;336:1121-1123.
17. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338: b1665.
18. Malacco E, Varì N, Capuano V, Spagnuolo V, Borgnino C, Palatini P; Val-Syst study. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: The Val-Syst study. Clin Ther. 2003;25:2765-2780.
19. Lacourcière Y. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension. Clin Ther. 2000;22:1213-1224.
20. Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged > or = 65 years with systolic hypertension. Clin Ther. 2000;22:961-969.
21. Neldam S, Forsén B; Multicentre Study Group. Antihypertensive treatment in elderly patients aged 75 years or over: A 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging. 2001;18:225-232.
22. Ruilope L, Jäger B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: A double-blind, randomized trial. Blood Press. 2001;10:223-229.
23. Volpe M, Junren Z, Maxwell T, Rodriguez A, Gamboa R, Gomez-Fernandez P, et al. CDSP - 944 Study Group. Comparison of the blood pressure-lowering effects and tolerability of losartan-and amlodipine-based regimens in patients with isolated sistoli hypertension. Clin Ther. 2003;25:1469-1489.
24. Neldam S, Edwards C; ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: Results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol. 2006;15:151-160.
25. Malacco E, Santonastaso M, Varí NA, Gargiulo A, Spagnuolo V, Bertocchi F, et al. Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: The Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther. 2004;26:855-865.
26. Williams B, Lacourcière Y, Schumacher H, Gosse P, Neutel JM. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: A pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009;23:610-619.
27. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 1995;17:911-923.
28. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 1999;6:161-166.
29. Destro M, Preti P, D'Ospina A, Christian Achiri NN, Ricci AR, Cagnoni F. Olmesartan medoxomil: Recent clinical and experimental acquisitions. Expert Opin Drug Metab Toxicol. 2009;5:1149-1157.
30. Scott LJ, McCormack PL. Olmesartan medoxomil: A review of its use in the management of hypertension. Drugs. 2008;68:1239-1272.
31. Heagerty AM, Mallion JM. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: Efficacy and safety data from clinical trials. Drugs Aging. 2009;26:61-76.
32. Mallion JM, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens. 2007;25:2168-2177.
33. O'Brien E, Pickering T, Asmar R, Myers M, Parati G, Staessen J, et al. Working Group on Blood Pressure Monitoring of the European Society of Hypertension. Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit. 2002;7:3-17.
34. Parati G, Omboni S, Palatini P, Rizzoni D, Bilo G, Valentini M, et al. Italian Society of Hypertension guidelines for conventional and automated blood pressure measurement in the office, at home and over 24 hours. High Blood Press Cardiovasc Prev. 2008;15:283-310.
35. Rizzoni D, Castellano M, Muiesan ML, Porteri E, Agabiti-Rosei E. Beyond trough: peak ratio: A new index of the smoothness of the antihypertensive effect of a drug. High Blood Press. 1997, 6:110-115.
36. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: A new, reproducible and officially relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685-1691.
37. Omboni S, Parati G, Mancia G. The trough: peak ratio and the smoothness index in the evaluation of control of 24h blood pressure by treatment in hypertension. Blood Press Monit. 1998;3:201-204.
38. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Anti-hypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25:1327-1336.
39. Sellin L, Stegbauer J, Laeis P, Rump LC. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens. 2005;23:2083-2092.
40. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5:41-50.
41. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens. 1995;8:311-315.
42. Mallion JM, Maitre A, de Gaudemaris R, Siché JP, Tremel F. Use of ambulatory blood pressure monitoring in the management of antihypertensive therapy. Drugs. 1992;44 Suppl 1:12-16.
43. Coats AJ, Conway J, Somers VK, Isea JE, Sleight P. Ambulatory pressure monitoring in the assessment of antihypertensive therapy. Cardiovasc Drugs Ther. 1989;3 Suppl 1:303-311.